However, systemic delivery of IL-15 has failed to progress through clinical development because of dose-limiting toxicity, and the future of IL-15 therapies will require innovations such as potency attenuation and antibody targeting or masking/tumor conditional activation to reduce systemic activity and direct IL-15R agonism to effector cells at the site of disease [99–101]. Here, IL15 is linked to neoplasm.